𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The prognostic value of tetranectin immunoreactivity and plasma tetranectin in patients with ovarian cancer

✍ Scribed by Claus K. H⊘gdall; Lise Christensen; Inge Clemmensen


Publisher
John Wiley and Sons
Year
1993
Tongue
English
Weight
795 KB
Volume
72
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis


Background. Tetranectin (TN), a tetrameric, plasminogen-binding protein, was reduced in the plasma of patients with cancer and appears extracellularly in "stimulated" connective tissues, such as the proliferative, connective tissue response to carcinomas known as desmoplasia.

Methods. Tissue samples from 37 patients with ovarian cancer were examined immunohistochemically for stromal and cellular TN. Plasma samples obtained before the primary surgery were quantitated for TN. The univariate log-rank test and the multivariate Cox proportional hazards regression model were used to analyze the prognostic function of the variables.

Results. A significantly higher survival rate was found for patients with a low-stromal TN score and a high-plasma TN concentration, whereas the cellular TN score did not have any significance. A significant negative correlation was found between plasma TN and stro-ma1 TN (R, = -0.36; P = 0.03). Independent significant correlations were found between stromal immunoreactivity for TN and tumor grade (R = 0.67; P = 0.03) and between plasma TN and tumor stage (R = -0.29; P = 0.01).

Conclusions. This study gives great expectations to TN as a useful parameter for prognostic evaluation of patients with ovarian cancer. According to the correlations, stromal TN may partly originate from plasma and enhance proteolytic degradation in the interstitial tissue, a process necessary for the spread and growth of cancer.


📜 SIMILAR VOLUMES


Distribution of HER-2 overexpression in
✍ Estrid V. S. Høgdall; Lise Christensen; Susanne K. Kjaer; Jan Blaakaer; Johannes 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 389 KB 👁 2 views

## Abstract ## BACKGROUND The HER‐2 (Human Epidermal Growth factor receptor‐2, also known as c‐__erb__‐2/__neu__) protooncogene encodes a transmembrane receptor protein, __M__~r~ 185,000. Studies have shown that the HER‐2 oncogene is overexpressed in approximately 25–30% of ovarian carcinoma (OC)

The prognostic value of clinical, pathol
✍ Soo Keat Khoo; Diana Battistutta; Terence Hurst; Barbara Sanderson; Bruce G Ward 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 704 KB

## Background: The prognosis in ovarian cancer remains poor, and there is a need to identify patients who are less likely to respond to treatment. ## Methods: In a study of 133 unselected patients with ovarian adenocarcinoma treated by a standard protocol, variables such as age, tumor type, inter